NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis → This Wall Street stock prediction just went viral (From Chaikin Analytics) (Ad) Free ACXP Stock Alerts $2.25 +0.16 (+7.66%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$2.14▼$2.3650-Day Range$1.64▼$2.9752-Week Range$1.17▼$8.82Volume170,421 shsAverage Volume140,986 shsMarket Capitalization$35.46 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Acurx Pharmaceuticals alerts: Email Address Acurx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside433.3% Upside$12.00 Price TargetShort InterestBearish4.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.69Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($2.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.86 out of 5 starsMedical Sector644th out of 928 stocksPharmaceutical Preparations Industry307th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.67% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 6.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 3.2 News and Social Media Coverage News SentimentAcurx Pharmaceuticals has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest22 people have searched for ACXP on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.97) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 6.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACXP Stock News HeadlinesMay 15 at 9:56 PM | morningstar.comAcurx Pharmaceuticals Inc Ordinary SharesMay 15 at 10:02 AM | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04May 15 at 9:00 AM | prnewswire.comAcurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionMay 15 at 7:00 AM | prnewswire.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comAcurx Pharmaceuticals (ACXP) Scheduled to Post Quarterly Earnings on WednesdayMay 2, 2024 | finance.yahoo.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 2, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceApril 23, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdateApril 17, 2024 | nasdaq.comAcurx Pharmaceuticals Rings the Closing BellMarch 20, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | markets.businessinsider.comAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic PartnershipsMarch 19, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.comQ4 2023 Acurx Pharmaceuticals Inc Earnings CallMarch 18, 2024 | investorplace.comACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023March 18, 2024 | finance.yahoo.comWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth CarefullyMarch 18, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 4, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business UpdateFebruary 27, 2024 | finance.yahoo.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 27, 2024 | prnewswire.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 17, 2024 | finance.yahoo.comACXP Mar 2024 4.000 callFebruary 16, 2024 | finance.yahoo.comACXP Mar 2024 5.000 putFebruary 2, 2024 | finance.yahoo.comNew to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PTFebruary 1, 2024 | finance.yahoo.comNew to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PTJanuary 26, 2024 | finance.yahoo.comNew to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PTSee More Headlines Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today5/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+433.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-289.69% Return on Assets-185.19% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book6.62Miscellaneous Outstanding Shares15,760,000Free Float10,195,000Market Cap$35.46 million OptionableOptionable Beta-1.79 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert J. DeLuccia (Age 78)Co-Founder & Executive Chairman Comp: $701.54kMr. David P. Luci CPA (Age 57)Esq., J.D., Co-Founder, President, CEO & Director Comp: $668.98kMr. Robert G. Shawah CPA (Age 57)CPA, Co-Founder & CFO Comp: $470.29kKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPBriaCell TherapeuticsNASDAQ:BCTXFortress BiotechNASDAQ:FBIOAprea TherapeuticsNASDAQ:APRESpruce BiosciencesNASDAQ:SPRBView All CompetitorsInstitutional OwnershipProspect Financial Services LLCBought 17,700 shares on 4/23/2024Ownership: 1.732%NBC Securities Inc.Bought 14,000 shares on 4/5/2024Ownership: 0.089%Prospect Financial Services LLCBought 255,150 shares on 2/20/2024Ownership: 1.853%View All Institutional Transactions ACXP Stock Analysis - Frequently Asked Questions Should I buy or sell Acurx Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACXP shares. View ACXP analyst ratings or view top-rated stocks. What is Acurx Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 12 month price objectives for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 433.3% from the stock's current price. View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts. How have ACXP shares performed in 2024? Acurx Pharmaceuticals' stock was trading at $3.83 at the start of the year. Since then, ACXP shares have decreased by 41.3% and is now trading at $2.25. View the best growth stocks for 2024 here. When is Acurx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ACXP earnings forecast. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) issued its quarterly earnings data on Friday, March, 15th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.12. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. Who are Acurx Pharmaceuticals' major shareholders? Acurx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Prospect Financial Services LLC (1.73%), NBC Securities Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACXP) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe ExchangeRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
